{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:24:32Z","timestamp":1791563072499,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006458","name":"Children's Hospital of Philadelphia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bbi.2026.106513","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:54:59Z","timestamp":1771865699000},"page":"106513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Neuroinflammation as a driver of Down syndrome-associated Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9317-4488","authenticated-orcid":false,"given":"Hui-Qi","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asbjorg Osk","family":"Snorradottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Gutierrez-Uzquiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlly","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakon","family":"Hakonarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2026.106513_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.718426","article-title":"Innate immune system activation and neuroinflammation in Down syndrome and neurodegeneration: therapeutic targets or partners?","volume":"13","author":"Ahmed","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bbi.2026.106513_b0010","first-page":"132","article-title":"Thyroid disorders in subjects with down syndrome: an update","volume":"89","author":"Amr","year":"2018","journal-title":"Acta Bio-Med.: Atenei Parmensis"},{"key":"10.1016\/j.bbi.2026.106513_b0015","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nn.4132","article-title":"Depletion of microglia and inhibition of exosome synthesis halt tau propagation","volume":"18","author":"Asai","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbi.2026.106513_b0020","article-title":"Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp (16) 1\/Yey mouse models of Down syndrome","volume":"11","author":"Aziz","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.bbi.2026.106513_b0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13024-021-00474-z","article-title":"Proteomic landscape of Alzheimer\u2019s Disease: novel insights into pathogenesis and biomarker discovery","volume":"16","author":"Bai","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bbi.2026.106513_b0030","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1172\/JCI95145","article-title":"Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives","volume":"128","author":"Baker","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbi.2026.106513_b0035","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1474-4422(16)00063-6","article-title":"Dementia in Down's syndrome","volume":"15","author":"Ballard","year":"2016","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/j.bbi.2026.106513_b0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.freeradbiomed.2017.07.009","article-title":"Disturbance of redox homeostasis in Down syndrome: role of iron dysmetabolism","volume":"114","author":"Barone","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbi.2026.106513_b0045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(13)62062-0","article-title":"Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial","volume":"383","author":"Bateman","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bbi.2026.106513_b0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2018.03.003","article-title":"Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease","volume":"319","author":"Bekris","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2026.106513_b0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuron.2010.09.043","article-title":"Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging","volume":"68","author":"Bell","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.bbi.2026.106513_b0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ridd.2016.06.018","article-title":"Overweight and obesity in children and adolescents with down syndrome-prevalence, determinants, consequences, and interventions: a literature review","volume":"57","author":"Bertapelli","year":"2016","journal-title":"Res. Dev. Disabil."},{"key":"10.1016\/j.bbi.2026.106513_b0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5698\/1535-7511.17.3.134","article-title":"\u201cAutoimmune epilepsy\u201d: encephalitis with autoantibodies for epileptologists","volume":"17","author":"Bien","year":"2017","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.bbi.2026.106513_b0070","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-018-0543-y","article-title":"Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline","volume":"562","author":"Bussian","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bbi.2026.106513_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1016872","article-title":"Alterations in intestinal microbiota and metabolites in individuals with down syndrome and their correlation with inflammation and behavior disorders in mice","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bbi.2026.106513_b0080","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/ars.2011.3895","article-title":"Amyloid beta induces oxidative stress-mediated blood\u2013brain barrier changes in capillary amyloid angiopathy","volume":"15","author":"Carrano","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bbi.2026.106513_b0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","article-title":"Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation","volume":"20","author":"Chen","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bbi.2026.106513_b0090","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.2147\/JIR.S280953","article-title":"Interferon-driven immune dysregulation in Down syndrome: a review of the evidence","volume":"14","author":"Chung","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.bbi.2026.106513_b0095","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbi.2026.106513_b0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bbi.2026.106513_b0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.bbi.2026.106513_b0110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mnfr.201300325","article-title":"Epigallocatechin\u20103\u2010gallate, a DYRK1A inhibitor, rescues cognitive deficits in D own syndrome mouse models and in humans","volume":"58","author":"De la Torre","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.bbi.2026.106513_b0115","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.3390\/ijms252010911","article-title":"Blood-based biomarkers in Alzheimer\u2019s disease: advancing non-invasive diagnostics and prognostics","volume":"25","author":"Dhauria","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbi.2026.106513_b0120","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fnins.2020.00670","article-title":"Down syndrome is a metabolic disease: altered insulin signaling mediates peripheral and brain dysfunctions","volume":"14","author":"Dierssen","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bbi.2026.106513_b0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s disease","volume":"388","author":"Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2026.106513_b0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.freeradbiomed.2013.01.016","article-title":"Chronic high levels of the RCAN1-1 protein may promote neurodegeneration and Alzheimer disease","volume":"62","author":"Ermak","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbi.2026.106513_b0135","doi-asserted-by":"crossref","DOI":"10.1002\/alz.075677","article-title":"Modelling of the development and response to amyloid-\u03b2 accumulation in the context of trisomy21 in the rodent brain","volume":"19","author":"Farrell","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bbi.2026.106513_b0140","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/brain\/awt110","article-title":"Disease-specific molecular events in cortical multiple sclerosis lesions","volume":"136","author":"Fischer","year":"2013","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.bbi.2026.106513_b0145","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1093\/brain\/awaa326","article-title":"Evolution of neuroinflammation across the lifespan of individuals with down syndrome","volume":"143","author":"Flores-Aguilar","year":"2020","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.bbi.2026.106513_b0150","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","article-title":"Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study","volume":"17","author":"Fortea","year":"2018","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/j.bbi.2026.106513_b0155","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","article-title":"Inflammaging: a new immune\u2013metabolic viewpoint for age-related diseases","volume":"14","author":"Franceschi","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bbi.2026.106513_b0160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainres.2006.06.042","article-title":"Protective effect of N-acetyl-L-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice","volume":"1109","author":"Fu","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.bbi.2026.106513_b0165","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg6218","article-title":"Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition","volume":"9","author":"Galbraith","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbi.2026.106513_b0170","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, Double-Blind Clinical Trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.bbi.2026.106513_b0175","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.25002","article-title":"Periodontal disease in Down syndrome: predisposing factors and potential non-surgical therapeutic approaches","volume":"38","author":"Ghaffarpour","year":"2024","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.bbi.2026.106513_b0180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.freeradbiomed.2004.09.025","article-title":"N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress","volume":"38","author":"Grinberg","year":"2005","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbi.2026.106513_b0185","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awr128","article-title":"Oxidative damage in multiple sclerosis lesions","volume":"134","author":"Haider","year":"2011","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.bbi.2026.106513_b0190","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(11)61676-0","article-title":"Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial","volume":"379","author":"Hanney","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbi.2026.106513_b0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40478-017-0499-4","article-title":"Cerebrovascular pathology in Down syndrome and Alzheimer disease","volume":"5","author":"Head","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bbi.2026.106513_b0200","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-180589","article-title":"Microbleeds and cerebral amyloid angiopathy in the brains of people with Down syndrome with Alzheimer's disease","volume":"67","author":"Helman","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbi.2026.106513_b0205","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nri3705","article-title":"Innate immune activation in neurodegenerative disease","volume":"14","author":"Heneka","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbi.2026.106513_b0210","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1242\/dmm.029728","article-title":"Rodent models in Down syndrome research: impact and future opportunities","volume":"10","author":"Herault","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.bbi.2026.106513_b0215","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1183\/20734735.012116","article-title":"Obstructive sleep apnoea\/hypopnoea syndrome in adults with Down syndrome","volume":"12","author":"Hill","year":"2016","journal-title":"Breathe (Sheff.)"},{"key":"10.1016\/j.bbi.2026.106513_b0220","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1126\/science.aad8373","article-title":"Complement and microglia mediate early synapse loss in alzheimer mouse models","volume":"352","author":"Hong","year":"2016","journal-title":"Science (New York N.Y.)"},{"key":"10.1016\/j.bbi.2026.106513_b0225","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamaneurol.2022.1740","article-title":"Detection of brain tau pathology in down syndrome using plasma biomarkers","volume":"79","author":"Janelidze","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bbi.2026.106513_b0230","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neurobiolaging.2014.10.038","article-title":"Periodontal disease associates with higher brain amyloid load in normal elderly","volume":"36","author":"Kamer","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbi.2026.106513_b0235","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"The Lancet Rheumatol."},{"key":"10.1016\/j.bbi.2026.106513_b0240","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3233\/JAD-210381","article-title":"Gut microbiota and Alzheimer\u2019s disease: pathophysiology and therapeutic perspectives","volume":"83","author":"Li","year":"2021","journal-title":"J. Alzheimer\u2019s Disease"},{"key":"10.1016\/j.bbi.2026.106513_b0245","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1038\/s41467-021-24319-x","article-title":"Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer\u2019s disease in adults with Down syndrome","volume":"12","author":"Lle\u00f3","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbi.2026.106513_b0250","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.expneurol.2015.08.018","article-title":"Microglia in the TBI brain: the good, the bad, and the dysregulated","volume":"275","author":"Loane","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbi.2026.106513_b0255","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ygeno.2007.08.005","article-title":"Gene expression profiling in the adult Down syndrome brain","volume":"90","author":"Lockstone","year":"2007","journal-title":"Genomics"},{"key":"10.1016\/j.bbi.2026.106513_b0260","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13195-024-01599-1","article-title":"Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease","volume":"16","author":"Long","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.bbi.2026.106513_b0265","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1073\/pnas.2009680117","article-title":"The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer\u2019s disease","volume":"117","author":"Lonnemann","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbi.2026.106513_b0270","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","article-title":"Dementia in Down syndrome: unique insights for Alzheimer disease research","volume":"15","author":"Lott","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"116\u2013130","key":"10.1016\/j.bbi.2026.106513_b0275","first-page":"e117","article-title":"Down-syndrome-induced senescence disrupts the nuclear architecture of neural progenitors","volume":"29","author":"Meharena","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbi.2026.106513_b0280","article-title":"Results from a phase 1 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ANX005, a C1q Inhibitor, in patients with Guillain-Barr\u00e9 Syndrome","volume":"30","author":"Mohammad","year":"2025","journal-title":"J. Peripheral Nervous Syst.: JPNS"},{"key":"10.1016\/j.bbi.2026.106513_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169305","article-title":"Symptomatic and disease-modifying therapy pipeline for Alzheimer's disease: towards a personalized polypharmacology patient-centered approach","volume":"23","author":"Morat\u00f3","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbi.2026.106513_b0290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.pbr.2019.08.001","article-title":"Modeling Down syndrome in animals from the early stage to the 4.0 models and next","volume":"251","author":"Moreno","year":"2020","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.bbi.2026.106513_b0295","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbi.2026.106513_b0300","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12840","article-title":"Tau protein aggregation is associated with cellular senescence in the brain","volume":"17","author":"Musi","year":"2018","journal-title":"Aging Cell"},{"key":"10.1016\/j.bbi.2026.106513_b0305","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/s41598-018-20984-z","article-title":"DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives","volume":"8","author":"Neumann","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbi.2026.106513_b0310","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1471-4159.2004.02428.x","article-title":"A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis","volume":"89","author":"Offen","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2026.106513_b0315","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.neuron.2016.01.042","article-title":"Down syndrome Developmental brain transcriptome reveals defective oligodendrocyte differentiation and myelination","volume":"89","author":"Olmos-Serrano","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.bbi.2026.106513_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111824","article-title":"Cellular senescence and premature aging in Down syndrome","volume":"212","author":"Peng","year":"2023","journal-title":"Mech. Ageing Dev."},{"issue":"887\u2013904","key":"10.1016\/j.bbi.2026.106513_b0325","article-title":"Rescuing over-activated microglia restores cognitive performance in juvenile animals of the Dp (16) mouse model of Down syndrome","volume":"108","author":"Pinto","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.bbi.2026.106513_b0330","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/gps.587","article-title":"A 24\u2010week, double\u2010blind, placebo\u2010controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease\u2014pilot study","volume":"17","author":"Prasher","year":"2002","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106513_b0335","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14604","article-title":"Risk of Alzheimer's disease in Down syndrome: Insights gained by multi-omics","volume":"21","author":"Qu","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bbi.2026.106513_b0340","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.99323","article-title":"JAK inhibition decreases the autoimmune burden in Down syndrome","volume":"13","author":"Rachubinski","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.bbi.2026.106513_b0345","doi-asserted-by":"crossref","DOI":"10.1002\/alz.092032","article-title":"Selection of biomarkers and clinical endpoints for clinical trials targeting Down syndrome\u2010related Alzheimer\u2019s disease (DSAD)","volume":"20","author":"Rafii","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bbi.2026.106513_b0350","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamaneurol.2022.0983","article-title":"Safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with down syndrome: a phase 1b randomized clinical trial","volume":"79","author":"Rafii","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bbi.2026.106513_b0355","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JAD-142499","article-title":"A phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer's disease","volume":"45","author":"Remington","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.bbi.2026.106513_b0360","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70330","article-title":"Gut dysbiosis in Down syndrome: a potentially unexplored culprit for early Alzheimer's disease","volume":"21","author":"Rosas","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bbi.2026.106513_b0365","article-title":"Antioxidants in Down syndrome: from preclinical studies to clinical trials","volume":"9","author":"Rueda Revilla","year":"2020","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"10.1016\/j.bbi.2026.106513_b0370","doi-asserted-by":"crossref","first-page":"34850","DOI":"10.1074\/jbc.M707358200","article-title":"DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease","volume":"282","author":"Ryoo","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbi.2026.106513_b0375","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/antiox10040573","article-title":"Treating neurodegenerative disease with antioxidants: Efficacy of the bioactive phenol resveratrol and mitochondrial-targeted MitoQ and SkQ","volume":"10","author":"Shinn","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.bbi.2026.106513_b0380","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.646924","article-title":"Cellular senescence in brain aging","volume":"13","author":"Sikora","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bbi.2026.106513_b0385","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13195-022-00999-5","article-title":"Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid \u03b2 plaque formation in mice","volume":"14","author":"Simon","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.bbi.2026.106513_b0390","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1038\/s41467-021-23243-4","article-title":"A meta-analysis of epigenome-wide association studies in Alzheimer's disease highlights novel differentially methylated loci across cortex","volume":"12","author":"Smith","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbi.2026.106513_b0395","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamaneurol.2025.0326","article-title":"N-Acetylcysteine for hereditary cystatin C amyloid angiopathy: a nonrandomized clinical trial","volume":"82","author":"Snorradottir","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bbi.2026.106513_b0400","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13291","article-title":"The historical background of hereditary cystatin C amyloid angiopathy: genealogical, pathological, and clinical manifestations","volume":"35","author":"Snorradottir","year":"2025","journal-title":"Brain Pathol."},{"key":"10.1016\/j.bbi.2026.106513_b0405","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.brainres.2015.06.019","article-title":"Parenchymal cystatin C focal deposits and glial scar formation around brain arteries in hereditary cystatin C amyloid angiopathy","volume":"1622","author":"Snorradottir","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.bbi.2026.106513_b0410","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bbi.2026.106513_b0415","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1172\/JCI81108","article-title":"Endothelial LRP1 transports amyloid-\u03b2(1-42) across the blood-brain barrier","volume":"126","author":"Storck","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbi.2026.106513_b0420","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.trci.2018.10.006","article-title":"Alzheimer's disease in Down syndrome: an overlooked population for prevention trials","volume":"4","author":"Strydom","year":"2018","journal-title":"Alzheimer's Dementia: Transl. Res. Clin. Intervent."},{"key":"10.1016\/j.bbi.2026.106513_b0425","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16220","article-title":"Trisomy 21 consistently activates the interferon response","volume":"5","author":"Sullivan","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.bbi.2026.106513_b0430","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbi.2026.106513_b0435","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5581139","article-title":"Peripheral oxidation markers in Down syndrome patients: the better and the worse","volume":"2021","author":"Szwajgier","year":"2021","journal-title":"Dis. Markers"},{"key":"10.1016\/j.bbi.2026.106513_b0440","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26030944","article-title":"Elamipretide: a review of its structure, mechanism of action, and therapeutic potential","volume":"26","author":"Tung","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbi.2026.106513_b0445","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2017.08.014","article-title":"Mitochondria as pharmacological targets in down syndrome","volume":"114","author":"Valenti","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbi.2026.106513_b0450","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00401-008-0419-6","article-title":"The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in down syndrome","volume":"116","author":"Wegiel","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbi.2026.106513_b0455","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2826.2008.01733.x","article-title":"Neurodevelopmental and neurophysiological actions of thyroid hormone","volume":"20","author":"Williams","year":"2008","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.bbi.2026.106513_b0460","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bbi.2026.106513_b0465","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/procel\/pwae026","article-title":"Alzheimer\u2019s disease: insights into pathology, molecular mechanisms, and therapy","volume":"16","author":"Zheng","year":"2024","journal-title":"Protein Cell"}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159126002618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159126002618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:19:48Z","timestamp":1781061588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159126002618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":93,"alternative-id":["S0889159126002618"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2026.106513","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroinflammation as a driver of Down syndrome-associated Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2026.106513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106513"}}